Up-regulation of glypican-3 in human hepatocellular carcinoma

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5055-5062

  Suzuki, Masahiro ^a   Sugimoto, Kazushi ^a   Tanaka, Junichiro ^a   Tameda, Masahiko ^a   Inagaki, Yuji ^a   Kusagawa, Satoko ^a   Nojiri, Keiichiro ^a   Beppu, Tetsuya ^a   Yoneda, Kentaro ^a   Yamamoto, Norihiko ^a   Ito, Masaaki ^a   Yoneda, Misao ^a   Uchida, Kazuhiko ^b   Takase, Koujiro ^a   Shiraki, Katsuya ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Differentiation; Glypican 3; GPC3; Hepatocellular carcinoma

Indexed keywords

GLYPICAN 3; MESSENGER RNA; SYNDECAN;

ARTICLE; BLOOD LEVEL; CELL MEMBRANE; CELL STRAIN HEPG2; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; HEPATITIS; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASES; LIVER NEOPLASMS; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; SYNDECANS; UP-REGULATION;

EID: 78751541473     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T and Nakatsura T: Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 100: 1403-1407,2009.
2. Nakajima M, Irimura T and Nicolson GL: Heparanases and tumor metastasis. J Cell Biochem 36: 157-167, 1988.
3. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, BarShavit R and Fuks Z: Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9: 203-226, 1990.
4. Hsu HC, Cheng W and Lai PL: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 57: 5179-5184, 1997.
5. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E and Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125: 8997,2003.
6. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, BeppuT, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y and Nishimura Y: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306: 16-25, 2003.
7. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M and Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103: 455465,2003.
8. Xiang YY, Ladeda V and Filmus J: Glypican-3 expression is silenced in human breast cancer. Oncogene 20: 7408-7412, 2001. (Pubitemid 33078211)
9. Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J and Testa JR: Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 19: 410-416, 2000.
10. Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ and Filmus J: OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 141: 1407-1414, 1998.
11. Lin H, Huber R, Schlessinger D and Morin PJ: Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 59: 807-810, 1995.
12. Roskams T, De Vos R, David G, Van Damme B and Desmet V: Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 185: 290-297, 1998. (Pubitemid 28320051)
13. Popović A, Demirović A, Spajić B, Stimac G, Kruslin B and Tomas D: Expression and prognostic role of syndecan-2 in prostate cancer. Prostate Cancer Prostatic Dis 13: 78-82, 2010.
14. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J and Büchler MW: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 45:558-564,2001.
15. Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R and Evans M: Glypican-3 immunocytochemistry in liver fine-needle aspirates. Cancer 111: 316-322, 2007.
16. Saleh HA, Aulicino M, Zaidi SY, Khan AZ and Masood S: Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel. Diagn Cytopathol 37: 184190,2009.
17. Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST and Yang XJ: Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med 132: 1723-1728, 2008.
18. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T.Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H and Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18: 1591-1598, 2005.
19. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L, Tornillo L, Vecchione R and Roncalli M: Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45: 725-734, 2007.
20. Song HH, Shi W, Xiang YY and Filmus J: The loss of glypican3 induces alterations in Wnt signaling. J Biol Chem 250: 2116-2125, 2005.
21. Yan D and Lin X: Drosophila glypican Dally-like acts in FGFreceiving cells to modulate FGF signaling during tracheal morphogenesis. Dev Biol 312: 203-216, 2007.
22. Capurro MI, Xu P, Shi W, Li F, Jia A and Filmus J: Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell 14: 700-711, 2008. (Pubitemid 351622615)
23. Filmus J, Capurro M and Rast J: Glypicans. Genome Biol 9: 224, 2008.
24. Capurro MI, Xiang YY, Lobe C and Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65: 6245-6254, 2005.
25. Capurro MI, Shi W, Sandal S and Filmus J: Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. J Biol Chem 250: 41201-4126, 2005.
26. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-5954, 2002.
27. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008,2002.
28. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, Yamamoto N, Ito K, Masuya M and Takei Y: Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 363: 738-744, 2007.
29. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130: 1117-1128, 2006.
30. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, Karras JG and Zhang H: Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 12: 7140-7148, 2006. (Pubitemid 44974515)